Subtype
Diffuse Glioma
CI-CAN-00002519Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002519Explore in graph →
Clinical trials
2,804 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07821112 | Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®(ENDURANCE) | not yet recruiting | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07703436 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease | not yet recruiting | Phase 2 | 40 | Nuvation Bio Inc.INDUSTRY | 1 |
| Sep 22, 2026 |
| clinicaltrials |
| NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | not yet recruiting | Phase 1 / Phase 2 | 96 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | not yet recruiting | Phase 1 / Phase 2 | 97 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07349693 | Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma(Cerebraca-02/3) | not yet recruiting | Phase 2 / Phase 3 | 175 | Everfront Biotech Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07644312 | Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG | not yet recruiting | Phase 2 | 12 | Nationwide Children's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789379 | Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | not yet recruiting | Phase 2 | 94 | Wei JiangOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07762716 | Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy | not yet recruiting | Phase 1 / Phase 2 | 10 | BreakBio CorpINDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07758062 | Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma(ELITE) | not yet recruiting | Phase 2 | 140 | Tianjin Medical University General HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | not yet recruiting | Phase 2 | 138 | Dongguan People's HospitalOTHER_GOV | 0 | Aug 10, 2026 | clinicaltrials |
| NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | not yet recruiting | Phase 1 / Phase 2 | 113 | Jubilant Therapeutics Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | not yet recruiting | Phase 2 | 79 | Nationwide Children's HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07735819 | Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma | not yet recruiting | Phase 2 | 61 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07713745 | Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)(PRIME-NF2) | not yet recruiting | Phase 2 | 200 | Beijing Tiantan HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07715097 | Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT07707947 | Selumetinib for NF2-Related Schwannomatosis(ASSIST) | not yet recruiting | Phase 2 | 20 | Beijing Tiantan HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07707973 | Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma(Nimotuzumab) | not yet recruiting | Phase 2 | 50 | Tianjin First Central HospitalOTHER | 0 | Jul 16, 2026 | clinicaltrials |
| NCT07620548 | Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas | not yet recruiting | Phase 2 | 99 | Washington University School of MedicineOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07609472 | FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma | not yet recruiting | Phase 2 | 76 | FluoGuide A/SINDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT07605364 | Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer | not yet recruiting | Phase 2 / Phase 3 | 422 | Alliance for Clinical Trials in OncologyOTHER | 0 | May 26, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07567469 | A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 120 | Regeneron PharmaceuticalsINDUSTRY | 0 | May 5, 2026 | clinicaltrials |
| NCT07562971 | Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES)(FIDES) | not yet recruiting | Phase 1 / Phase 2 | 20 | UMC UtrechtOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07431216 | A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression | not yet recruiting | Phase 1 / Phase 2 | 68 | Starlight Therapeutics Inc.INDUSTRY | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.(PRC) | not yet recruiting | Phase 2 | 70 | The Cooper Health SystemOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT07365280 | Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 78 | ZSky Biotech IncINDUSTRY | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07347210 | Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma(MATVAC-1) | not yet recruiting | Phase 2 | 98 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04373785 | NG101m Adjuvant Therapy in Glioblastoma Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | NeuGATE TheranosticsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT07138001 | Phase 2 Clinical Trial of KH617 | not yet recruiting | Phase 2 | 60 | Sichuan Honghe Biotechnology Co., Ltd.INDUSTRY | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07120984 | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma(IMAGLIO) | not yet recruiting | Phase 2 | 52 | Philogen S.p.A.INDUSTRY | 0 | Aug 13, 2025 | clinicaltrials |
| NCT07047066 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 30 | Tongji HospitalOTHER | 0 | Jul 2, 2025 | clinicaltrials |
| NCT01777919 | Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform(GLIODIS) | not yet recruiting | Phase 2 | 32 | Olympion Medical CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06780592 | Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery | not yet recruiting | Phase 2 | 60 | Huashan HospitalOTHER | 0 | Jan 22, 2025 | clinicaltrials |
| NCT06258018 | Niraparib and Temozolomide in Patients Glioblastoma(ONC-2022-001) | not yet recruiting | Phase 1 / Phase 2 | 86 | Armando Santoro, MDOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06485908 | Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma(MEPENDAX) | not yet recruiting | Phase 1 / Phase 2 | 40 | Assistance Publique Hopitaux De MarseilleOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06218524 | The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM | not yet recruiting | Phase 2 | 200 | Southern Medical University, ChinaOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05540275 | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma | not yet recruiting | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05842746 | Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | not yet recruiting | Phase 2 | 74 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05502991 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | not yet recruiting | Phase 2 | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials